Radware (NasdaqGS:RDWR) 2026 Investor Day February 17, 2026 09:30 AM ET Company ParticipantsConnie Stack - Chief Growth OfficerDavid Aviv - CTORoy Zisapel - President and CEONone - Video NarratorModeratorHello, good morning. Good morning, everyone, and welcome to Radware's Investor Day. We are happy, excited, to host you here in person and also on the webcast. So in our agenda today, we'll start with Roy Zisapel, who will present the vision and the strategy. Followed by Connie Stack, who will present the gr ...

Trane Technologies FY Conference Summary Company Overview - **Company**: Trane Technologies (NYSE: TT) - **Date of Conference**: February 17, 2026 - **Speakers**: Dave Regnery (Chair and CEO), Chris Kuehn (CFO) Key Points Industry and Market Performance - **Commercial HVAC Orders**: Orders increased by over 22% in Q4 2025, with broad-based growth across multiple verticals including data centers, higher education, healthcare, and industrial sectors [2][3] - **Strong Pipeline**: The company reported a robust pipeline, indicating strong future growth potential, particularly in the commercial HVAC business [3] - **Geographic Strength**: Growth was noted not only in North America but also in Europe, highlighting a positive trend in international markets [3] Vertical Insights - **Higher Education and Industrial Sectors**: Despite concerns regarding stimulus money and demographic pressures, the higher education sector showed resilience with order growth in 12 of 14 tracked verticals. The industrial sector is also expected to benefit from mega projects and reshoring efforts [5][9] - **K-12 Education**: A slight contraction was observed, but the overall outlook remains positive with a strong pipeline [5][8] Market Share and Competitive Position - **Market Share Confidence**: The company expressed confidence in maintaining and potentially increasing market share through continuous investment in innovation and a direct sales approach [10][12] - **System-Level Approach**: Trane Technologies emphasizes a systems approach to product development, which differentiates it from competitors who may focus on individual components [14][20] Data Center Thermal Management - **Technological Leadership**: Trane is actively engaging with key influencers in the data center space to develop future thermal management systems, ensuring that chillers remain integral to these systems [17][18] - **Liquid Cooling Solutions**: The acquisition of LiquidStack enhances Trane's position in the cooling market, particularly in the CDU space [29] Residential Market Outlook - **Production Adjustments**: The company intentionally reduced production days in the residential business to align inventory levels, anticipating a challenging Q1 2026 compared to a strong Q1 2025 [35][36] - **Price Strategy**: A price increase of up to 5% was announced, effective April 1, to offset inflation and maintain margins [39][41] European Market Strategy - **Investment in Direct Sales**: Trane has made intentional investments in its European operations, focusing on direct sales and acquisitions to strengthen its market position [42][43] Financial Performance and Guidance - **Revenue Growth**: Trane Technologies reported a compound annual growth rate of double digits, with revenue increasing from $12.5 billion five years ago to $21.3 billion [64] - **Future Opportunities**: The company sees more opportunities ahead than in the past, indicating a positive outlook for growth [65] Innovation and Technology - **Service Technician Training**: An advanced service technician training center was opened to enhance service capabilities across various product lines [22][23] - **AI Integration**: The company is leveraging AI technologies to improve service efficiency and technician knowledge [31][32] Conclusion - Trane Technologies is positioned for continued growth through strategic investments, a strong focus on innovation, and a commitment to understanding customer needs across various sectors. The company remains optimistic about its market share and future opportunities in both traditional and emerging markets.

CNH Industrial (NYSE:CNH) Q4 2025 Earnings call February 17, 2026 09:00 AM ET Company ParticipantsAngel Castillo - Executive Director and Head of U.S. Machinery and Construction Equity ResearchDavid Raso - Senior Managing Director and PartnerGerrit Marx - CEOJason Omerza - VP of Investor RelationsJim Nickolas - CFOKristen Owen - Managing DirectorPeter Kalemkerian - Equity Research AssociateTami Zakaria - Executive DirectorConference Call ParticipantsDaniela Costa - Managing Director and Equity Research Anal ...

Financial Data and Key Metrics Changes - In 2025, the company achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [5][13] - For the fourth quarter, enterprise revenue increased by 5.6% year-over-year, with adjusted EPS growing by 18% [10][14] - Free cash flow from continuing operations was $490 million, a decrease from $665 million the previous year, primarily due to working capital timing [15] Business Line Data and Key Metrics Changes - Diagnostics revenue for the fourth quarter was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% [16] - Biopharma Laboratory Services (BLS) revenue increased by 3.4% year-over-year, with central lab revenue growing by 11.1% [17] - The adjusted operating income for diagnostics was $419 million, representing 15.4% of revenue, compared to 13.9% the previous year [16] Market Data and Key Metrics Changes - The company reported a strong trailing twelve-month book-to-bill ratio of 1.09, driven by central labs [13][18] - The backlog for BLS was $8.7 billion, with an expected conversion of approximately $2.7 billion into revenue over the next 12 months [18] Company Strategy and Development Direction - The company aims to deepen partnerships with health systems and local laboratories, having signed or closed 13 deals contributing to over $1 billion in revenue growth [5][6] - A strategic investment is planned for a new central laboratory facility to support growth and demand, with construction expected to begin later this year [9] - The company continues to focus on specialty testing, having launched over 130 new tests in 2025, particularly in oncology, women's health, and neurology [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [11][20] - The delay of PAMA through December 31, 2026, was viewed positively, but management emphasized the need for permanent reform [11][20] - Management highlighted the importance of ongoing investments in technology and AI to enhance customer experience and operational efficiency [9][21] Other Important Information - The company plans to allocate free cash flow for acquisitions, share repurchases, and dividends, with approximately $800 million of share repurchase authorization remaining [15][21] - Two executives are set to retire on April 1, with successors already appointed [11][12] Q&A Session Summary Question: 2026 guidance contributions from price and volume - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [26][27] Question: Contributions from Invitae integration - The integration of Invitae has been successful, with expected revenue growth in specialty areas, but specific breakout of Invitae's performance will no longer be provided [31][32] Question: Fourth quarter organic volume performance - Organic volume was impacted by lower referrals from a large consumer genetic client and weather conditions, but adjustments indicate growth would have been over 2% [36][37] Question: 2026 guidance conservativeness and risks - Management feels confident about the guidance but acknowledges potential variability in organic volumes and the timing of M&A [44][46] Question: Competitive landscape in diagnostics - The company believes it will outperform the overall market, focusing on hospital deals and specialty testing, which are expected to grow faster than the overall market [48][49] Question: PAMA implications and central lab investments - Management is prepared to submit data for PAMA and continues to advocate for the RESULTS Act, while also planning significant investments in central lab infrastructure [55][59]

Donnelley Financial Solutions (NYSE:DFIN) Q4 2025 Earnings call February 17, 2026 09:00 AM ET Company ParticipantsCharlie Strauzer - Senior Managing DirectorCraig Clay - President of Global Capital MarketsDan Leib - President and CEODave Gardella - CFOEric Johnson - President of Global Investment CompaniesMike Zhao - Head of Investor RelationsPete Heckmann - Managing DirectorRoss Cole - Equity Research AssociateOperatorI would now like to turn the conference over to Mike Zhao, Head of Investor Relations. Pl ...

Financial Data and Key Metrics Changes - The company achieved a consolidated net sales growth of 10.4% year-over-year in Q4 2025, with Adjusted EBITDA increasing by $14.1 million or approximately 44% year-over-year, resulting in an Adjusted EBITDA margin of 26.6%, up 630 basis points from the previous year [4][5][26] - For the full year 2025, consolidated Adjusted EBITDA reached $239.8 million, a 10.4% increase year-over-year, with an Adjusted EBITDA margin of 31.3%, up 350 basis points from 2024 [6][19] Business Line Data and Key Metrics Changes - Software solutions net sales grew by 8.7% year-over-year to $358.4 million, representing approximately 47% of total net sales for 2025 [9][19] - The capital market software solutions segment saw net sales of $60 million, a 20% increase year-over-year, driven by strong growth in Venue and Active Disclosure, both up approximately 20% [27] - The investment company's software solution segment reported net sales of $30.9 million, a decrease of 2.2% year-over-year, attributed to tough comparisons from a strong Q4 2024 [32] Market Data and Key Metrics Changes - The company recorded $48.6 million in transactional revenue in Q4 2025, a 29% increase year-over-year, benefiting from a recovery in deal completions following a government shutdown [30] - The company maintained a high market share for large IPOs, capturing 65% of IPOs that raised over $100 million in Q4 2025 [60] Company Strategy and Development Direction - The company is transitioning to chapter three of its transformation, focusing on sustained growth and increasing the mix of predictable revenue from recurring offerings [19][20] - The introduction of new products like ArcFlex and enhancements in AI capabilities are aimed at capturing additional market demand and improving operational efficiency [15][16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing momentum in capital markets and expects to capture an uptick in deal activity in 2026, despite a continued decline in print and distribution sales [20][38] - The company does not anticipate major SEC rule changes for 2026 but is well-positioned to capture demand from future regulations [22] Other Important Information - The company repurchased approximately 3.6 million shares in 2025, representing about 12% of outstanding shares, at an average price of $48.36 per share [4][36] - Free cash flow for Q4 was $47.9 million, with a full-year total of $107.8 million, reflecting improved operational performance [35] Q&A Session Summary Question: How much of the outperformance in Q4 was volume versus price? - Management indicated that the outperformance was predominantly driven by volume, particularly in capital markets transactional revenue, with a modest contribution from price [48] Question: Can you provide more color on the drivers behind the strong margins? - Management attributed the strong margins to a favorable sales mix, cost structure improvements, and operating leverage from increased sales, with long-term guidance for margins above 30% [50] Question: How does the potential opportunity in capital allocation look given recent valuation multiples? - Management noted that while valuations have contracted, there may be interesting opportunities as companies seek liquidity, and they continue to monitor the situation [52] Question: Can you discuss the relative TAM for ArcFlex compared to ArcSuite? - Management confirmed that ArcFlex can be sold as a standalone product, with significant interest in the market for alternative investment solutions [56] Question: What is the outlook for IPO activity and DFIN's share in traditional IPOs? - Management highlighted a strong share in larger IPOs, with a 70% share of offerings greater than $1 billion in 2025, indicating readiness to support complex deals [61]

Franklin Electric (NasdaqGS:FELE) Q4 2025 Earnings call February 17, 2026 09:00 AM ET Company ParticipantsDean Cantrell - Director of Investor RelationsJennifer Wolfenbarger - CFOJoe Ruzynski - CEOConference Call ParticipantsBryan Blair - Managing Director and Research AnalystMatt Summerville - Managing Director and Senior Research AnalystMike Halloran - Senior Research AnalystRyan Connors - Managing Director and Research AnalystWalter Liptak - Industrial AnalystOperatorHello, and welcome to the Franklin El ...

Energy Transfer (NYSE:ET) Q4 2025 Earnings call February 17, 2026 09:00 AM ET Company ParticipantsAdam Mackay - EVP of Crude OilDylan Bramhall - CFOMackie McCrea - Co-CEOThomas Long - CFOConference Call ParticipantsElvira Scotto - Equity Research AnalystGabe Moreen - Equity Research AnalystJason Gabelman - Equity Research AnalystJean Salisbury - Equity Research AnalystJohn Mackay - Equity Research AnalystJulien Dumoulin-Smith - Equity Research AnalystKeith Stanley - Equity Research AnalystManav Gupta - Equi ...

Labcorp (NYSE:LH) Q4 2025 Earnings call February 17, 2026 09:00 AM ET Company ParticipantsAdam Schechter - Chairman, President and CEOChristin O'Donnell - VP of Investor RelationsDan Clark - VP in Equity ResearchElizabeth Anderson - Senior Managing Director in Health Care Technology and Distribution ResearchErin Wright - Managing Director in U.S. Healthcare Services ResearchJack Meehan - Partner in Life Science Tools and Diagnostics ResearchJulia Wang - EVP and CFOKevin Caliendo - Managing Director in Healt ...

Financial Data and Key Metrics Changes - GAAP EPS for the fourth quarter was $9.05, including a tax benefit of $78.5 million, or $3.98 per share, primarily due to a U.S. tax deduction related to the Prospera investment [20] - Adjusted diluted EPS was $4.92, up 28.1% year-over-year [21] - For the full year, adjusted diluted EPS was $19.09, an increase of 11.1% over 2024 [30] Business Line Data and Key Metrics Changes - Infrastructure sales grew 7.2% year-over-year to $819 million, with utility sales increasing by 21% due to strong market conditions and higher volumes [24] - Agriculture sales decreased 19.9% year-over-year to $222.7 million, with an operating loss of $3.3 million in the fourth quarter [27] - Coatings sales increased by 6.3%, supported by healthy infrastructure demand [26] Market Data and Key Metrics Changes - The utility market is experiencing strong demand driven by electrification, AI, and aging infrastructure replacement, with a backlog of $1.5 billion, up 22% from the previous year [10][44] - North American agriculture markets remain challenged, while international sales declined due to economic conditions in Brazil [27][15] - The telecommunications market has normalized, with ongoing investments in wireless and RAN [72] Company Strategy and Development Direction - The company is focused on disciplined resource allocation, safety, and continuous improvement to enhance performance [9] - Investments in technology and aftermarket services are aimed at improving efficiency and customer experience in agriculture [8][16] - The company plans to host an investor day to share deeper insights into its strategy and long-term financial targets [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the utility market's strength, citing multiple demand drivers and a robust backlog [44] - The agriculture segment is expected to see a meaningful recovery in Q1 2026, with a focus on improving margins [45][49] - The company anticipates net sales for 2026 to be between $4.2 billion and $4.4 billion, with diluted EPS projected in the range of $20.50 to $23.50 [35][36] Other Important Information - The company acquired the remaining 40% of ConcealFab, enhancing its technology and product pipeline [12] - A total of $250 million was returned to shareholders, including $198 million through share repurchases [32] Q&A Session Summary Question: Confidence in utility demand and changes in customer investment - Management is confident in the utility market due to strong drivers like electrification and aging infrastructure, supported by a backlog of $1.5 billion [44] Question: Actions to restore agriculture margins and expected recovery timeline - Management expects a meaningful recovery in agriculture margins in Q1 2026, having taken steps to address previous challenges [45][46] Question: Capital spending increase for utility capacity expansions - The company plans to spend $170 million to $200 million in 2026 on utility capacity expansions, driven by durable demand [53][54] Question: Expected agriculture margins for Q1 and full year - Management anticipates low teens margins in Q1, potentially reaching mid-teens by year-end [51] Question: Growth expectations in non-utility infrastructure segments - Management expects growth across all infrastructure segments, including telecom, coatings, and lighting [72]